Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

Fidelis Care announced that it is using Men’s Health Month as an opportunity to promote important health tips that men should ...

The drinks contain a mix of protein and vitamins that will help GLP-1 users reduce weight in a healthy manner.

These diseases require specialty treatment typically unavailable at local retail pharmacies or small health systems, making ...

New drug application submission was based on positive data from the Phase III GLISTEN trial, which demonstrated significant ...

Approval was based on results from the Phase III ARANOTE trial, in which Nubeqa demonstrated a 46% reduction in the risk of ...

The industry is facing challenges from the new administration that could have serious impacts on everything from market ...

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

Poor investigator site selection remains a significant driver of spiraling costs and inefficiencies in clinical development.

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good ...

New data show that Uzedy significantly reduces relapse and healthcare utilization, while TEV-'749 has demonstrated strong ...

Approval was based on data from the Phase III NextCOVE trial, which demonstrated that mNEXSPIKE met non-inferiority criteria ...